Clinical impact of novel CMR technology on patients with congenital heart disease. A scientific statement of the Association for European Pediatric and Congenital Cardiology (AEPC) and the European Association of Cardiovascular Imaging (EACVI) of the ESC
Inga Voges,Francesca Raimondi,Colin J McMahon,Lamia Ait-Ali,Sonya V Babu-Narayan,René M Botnar,Barbara Burkhardt,Dominik D Gabbert,Lars Grosse-Wortmann,Hosan Hasan,Georg Hansmann,Willem A Helbing,Sylvia Krupickova,Heiner Latus,Nicola Martini,Duarte Martins,Vivek Muthurangu,Tiina Ojala,Pim van Ooij,Kuberan Pushparajah,Jose Rodriguez-Palomares,Samir Sarikouch,Heynric B Grotenhuis,F Gerald Greil,members of the 2022–2024 EACVI Scientific Documents Committee,Yohann Bohbot,Maja Cikes,Marc Dweck,Erwan Donal,Julia Grapsa,Niall Keenan,Aniela Monica Petrescu,Liliana Szabo,Fabrizio Ricci,Valtteri Uusitalo
DOI: https://doi.org/10.1093/ehjci/jeae172
2024-07-10
Abstract:Cardiovascular magnetic resonance (CMR) imaging is recommended in patients with congenital heart disease (CHD) in clinical practice guidelines as the imaging standard for a large variety of diseases. As CMR is evolving, novel techniques are becoming available. Some of them are already used clinically, whereas others still need further evaluation. In this statement the authors give an overview of relevant new CMR techniques for the assessment of CHD. Studies with reference values for these new techniques are listed in the supplement.